Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.
Nitz UA, Gluz O, Christgen M, Grischke EM, Augustin D, Kuemmel S, Braun M, Potenberg J, Kohls A, Krauss K, Stefek A, Schumacher C, Forstbauer H, Reimer T, Fischer H, Liedtke C, Wuerstlein R, Schumacher J, Kates R, Kreipe H, Harbeck N. Nitz UA, et al. Among authors: wuerstlein r. Ann Oncol. 2017 Nov 1;28(11):2768-2772. doi: 10.1093/annonc/mdx494. Ann Oncol. 2017. PMID: 28945833 Free article. Clinical Trial.
Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma.
Blobner J, Dengler L, Blobner S, Eberle C, Weller J, Teske N, Karschnia P, Rühlmann K, Heinrich K, Ziemann F, Greif PA, Jeremias I, Wuerstlein R, Hasselmann K, Dorostkar M, Harter PN, Quach S, Stoecklein V, Albert NL, Niyazi M, Tonn JC, Thon N, Christoph Westphalen B, von Baumgarten L. Blobner J, et al. Among authors: wuerstlein r. Neurooncol Adv. 2023 May 12;5(1):vdad060. doi: 10.1093/noajnl/vdad060. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37287694 Free PMC article.
Health-related quality of life in male breast cancer patients.
Kowalski C, Steffen P, Ernstmann N, Wuerstlein R, Harbeck N, Pfaff H. Kowalski C, et al. Among authors: wuerstlein r. Breast Cancer Res Treat. 2012 Jun;133(2):753-7. doi: 10.1007/s10549-012-1970-3. Breast Cancer Res Treat. 2012. PMID: 22315132
[Breast cancer. Individualized therapy concepts].
Harbeck N, Wuerstlein R. Harbeck N, et al. Among authors: wuerstlein r. Internist (Berl). 2013 Feb;54(2):194-9. doi: 10.1007/s00108-012-3156-9. Internist (Berl). 2013. PMID: 23371261 German.
Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstlein R, Fischer T, Schmitt M, Jaenicke F, Untch M, Thomssen C, Harbeck N. Jacobs VR, et al. Among authors: wuerstlein r. Breast Cancer Res Treat. 2013 Apr;138(3):839-50. doi: 10.1007/s10549-013-2496-z. Epub 2013 Apr 9. Breast Cancer Res Treat. 2013. PMID: 23568480 Clinical Trial.
144 results